(Total Views: 276)
Posted On: 12/09/2019 11:15:44 AM
Post# of 106

$APRE News Article - Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual https://marketwirenews.com/news-releases/apre...06741.html


My Twitter: WhyteStocks